BR112021022067A2 - Inibidores de kcnt1 e métodos de uso - Google Patents

Inibidores de kcnt1 e métodos de uso

Info

Publication number
BR112021022067A2
BR112021022067A2 BR112021022067A BR112021022067A BR112021022067A2 BR 112021022067 A2 BR112021022067 A2 BR 112021022067A2 BR 112021022067 A BR112021022067 A BR 112021022067A BR 112021022067 A BR112021022067 A BR 112021022067A BR 112021022067 A2 BR112021022067 A2 BR 112021022067A2
Authority
BR
Brazil
Prior art keywords
kcnt1
methods
disease
inhibitors
disorder
Prior art date
Application number
BR112021022067A
Other languages
English (en)
Inventor
Mark Griffin Andrew
Edward Marron Brian
Martinez Botella Gabriel
Kiran Reddy
Kristopher Mathieu Kahlig Michael
S Charifson Paul
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of BR112021022067A2 publication Critical patent/BR112021022067A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

processo de codificação e decodificação de uma imagem de uma sequência de vídeo e dispositivo associado. a presente invenção se refere, em parte, a compostos e composições úteis para prevenir e/ou tratar uma doença ou distúrbio neurológico, uma doença ou condição relacionada à excitabilidade neuronal excessiva e/ou uma mutação de ganho de função em um gene (por exemplo, kcnt1). são ainda fornecidos neste documento métodos de tratamento de uma doença ou distúrbio neurológico, uma doença ou condição relacionada à excitabilidade neuronal excessiva e/ou uma mutação de ganho de função em um gene, tal como kcnt1.
BR112021022067A 2019-05-03 2020-05-01 Inibidores de kcnt1 e métodos de uso BR112021022067A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
BR112021022067A2 true BR112021022067A2 (pt) 2022-05-17

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022067A BR112021022067A2 (pt) 2019-05-03 2020-05-01 Inibidores de kcnt1 e métodos de uso

Country Status (17)

Country Link
US (1) US20220259193A1 (pt)
EP (1) EP3962481A4 (pt)
JP (1) JP2022531388A (pt)
KR (1) KR20220016086A (pt)
CN (1) CN114269340A (pt)
AU (1) AU2020267356A1 (pt)
BR (1) BR112021022067A2 (pt)
CA (1) CA3139063A1 (pt)
CL (1) CL2021002877A1 (pt)
CO (1) CO2021016471A2 (pt)
EC (1) ECSP21087884A (pt)
IL (1) IL287768A (pt)
MX (1) MX2021013421A (pt)
PE (1) PE20220016A1 (pt)
SA (1) SA521430751B1 (pt)
SG (1) SG11202112158YA (pt)
WO (1) WO2020227101A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022530989A (ja) * 2019-05-03 2022-07-05 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤および使用する方法
US20230373937A1 (en) * 2020-09-09 2023-11-23 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2023239839A1 (en) * 2022-06-08 2023-12-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP2044061A2 (en) * 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
MX355945B (es) * 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
US10538516B2 (en) * 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
IL287768A (en) 2022-01-01
SG11202112158YA (en) 2021-12-30
CN114269340A (zh) 2022-04-01
CA3139063A1 (en) 2020-11-12
ECSP21087884A (es) 2022-01-31
SA521430751B1 (ar) 2024-02-01
WO2020227101A1 (en) 2020-11-12
EP3962481A4 (en) 2023-03-22
CO2021016471A2 (es) 2022-04-08
JP2022531388A (ja) 2022-07-06
CL2021002877A1 (es) 2022-08-12
KR20220016086A (ko) 2022-02-08
PE20220016A1 (es) 2022-01-11
AU2020267356A1 (en) 2022-01-06
EP3962481A1 (en) 2022-03-09
MX2021013421A (es) 2022-02-11
US20220259193A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
BR112021022067A2 (pt) Inibidores de kcnt1 e métodos de uso
BR112021022061A2 (pt) Inibidores de kcnt1 e métodos de uso
BR112019006106A2 (pt) formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio.
MX2019013172A (es) Composiciones y metodos para tratar la enfermedad de huntington.
MX2018014152A (es) Composiciones y métodos para tratar la enfermedad de huntington.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
BR112018007066A2 (pt) composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
PH12017500920B1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112022009938A2 (pt) Compostos macrocíclicos substituídos e métodos de tratamento relacionados
MX2021003706A (es) Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
BR112016021535A8 (pt) kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
BR112018075310A2 (pt) metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1
BR112021018688A2 (pt) Composição para prevenir ou tratar doença cerebral e do sistema nervoso
BR112018001782A2 (pt) oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
BR112019000946A2 (pt) compostos para imagiologia dos agregados da proteína tau
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
BR112022017191A2 (pt) Inibidores de kcnt1 e métodos de uso
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MA53564A (fr) Procédés de traitement d'infections mycobactériennes à l'aide de composés de tétracycline
BR112021019901A2 (pt) Método para tratar síndrome de abstinência neonatal devido à retirada de opioides
MX2022013383A (es) Composiciones y metodo para tratar la depresion.